Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O75916
UPID:
RGS9_HUMAN
Alternative names:
-
Alternative UPACC:
O75916; A8K3C0; O75573; Q696R2; Q8TD64; Q8TD65; Q9HC32; Q9HC33
Background:
Regulator of G-protein signaling 9 (RGS9) plays a pivotal role in the visual system by accelerating the deactivation of G proteins, thereby facilitating the rapid recovery of photoreceptors to their pre-activated state. This process is crucial for the ability of eyes to adjust to varying light conditions.
Therapeutic significance:
RGS9 is linked to Prolonged electroretinal response suppression 1 (PERRS1), a disorder that affects vision adaptation in changing luminance. Understanding RGS9's function could lead to novel treatments for PERRS1, enhancing quality of life for those affected.